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Background: Ischaemic heart disease (IHD) is the leading cause of death worldwide. TheWorld Health Organisa-
tion (WHO) collects mortality data coded using the International Statistical Classiﬁcation of Diseases (ICD) code.
Methods:We analysed IHD deaths world-wide between 1995 and 2009 and used the UN population database to
calculate age-speciﬁc and directly and indirectly age-standardised IHD mortality rates by country and region.
Results: IHD is the single largest cause of death worldwide, causing 7,249,000 deaths in 2008, 12.7% of total glob-
al mortality. There is more than 20-fold variation in IHDmortality rates between countries. Highest IHDmortal-
ity rates are in Eastern Europe and Central Asian countries; lowest rates in high income countries. For the
working-age population, IHD mortality rates are markedly higher in low-and-middle income countries than
in high income countries.
Over the last 25 years, age-standardised IHD mortality has fallen by more than half in high income countries,
but the trend is ﬂat or increasing in some low-and-middle income countries. Low-and-middle income countries
now account for more than 80% of global IHD deaths.
Conclusions: The global burden of IHD deaths has shifted to low-and-middle income countries as lifestyles ap-
proach those of high income countries. In high income countries, population ageingmaintains IHD as the leading
cause of death. Nevertheless, the progressive decline in age-standardised IHDmortality in high income countries
shows that increasing IHD mortality is not inevitable. The 20-fold mortality difference between countries, and
the temporal trends, may hold vital clues for handling IHD epidemic which is migratory, and still burgeoning.© 2012 Elsevier Ireland Ltd. Open access under CC BY license.1. Introduction
Ischaemic heart disease (IHD) is the leading cause of death world-
wide [1–4], placing a major economic and resource burden on health
and public health systems. High income countries have seen declines
in mortality rates from IHD [5–10], but elsewhere the picture is less
favourable, with continued high IHD mortality [11]. Reliable informa-
tion describing time-trends in IHD mortality is essential to understand
and monitor the disease [12]. In this article we provide an overview of
the global epidemiology of IHDmortality using data submitted by indi-
vidual member states to theWorld Health Organisation. The data covers supported by the British Heart
hD Fellowship 092853/Z/10/Z.
ational Centre for Circulatory
nstitute, London, UK. Tel.: +44
negold).
r CC BY license.the period 1995 to 2009, and are more complete for some countries
than for others. We have analysed the data to allow identiﬁcation of
country-speciﬁc and broad regional trends.
We present absolute IHD burden, along with directly and indirect-
ly standardised IHD mortality rates. Absolute burden reﬂects the total
number of deaths a health system has to deal with, which will tend to
be larger in more populous countries. Standardised rates are preferable
for comparing countries because they remove the effects of population
size and age structure. The most comprehensive standardisation is
direct standardisation (Fig. 1), which requires age-speciﬁc data for
both the number of deaths in each country and its population size. In
many countries age-speciﬁc data on deaths from IHD are not available,
but the UN does provide modelled estimates of age-speciﬁc population
counts for all countries. Indirect standardisation (Fig. 2) divides the
deaths observed in a country, by the deaths expected if that country
had the same age-speciﬁc death rates as a population group chosen to
be the standard for comparison. We present indirectly standardised ra-
tios for countries where direct standardisation is not possible due to
lack of age-speciﬁc death data.
Fig. 1. (a) A standard population of 2000 people, distributed equally amongst "young" (under 60 years) and "old" (60 years and older) groups which have different death rates. This
distribution of ages will be used as the "standard" in the other panels. (b) A country with the same age-speciﬁc risks, but whose population is older. Crude death rate is higher be-
cause a greater proportion of people are in the high-risk age group. However, age-standardisation prevents the ageing artefact by reconstituting a population of the "standard" age
distribution, to obtain the same standardised death rate as (a). (c) A country which, compared with (a), has double the death rate at each age group. Crude death rates, and
age-standardised death rates are doubled (d) A country with double the age-speciﬁc mortality and an older population. Crude mortality is very much higher but age-standardised
mortality, which reconstitutes a standard distribution of ages, is only twice that of panel (a).
Fig. 2. If a country reports age-speciﬁc population but only total IHD deaths (without an age breakdown), it is not possible to calculate directly standardised mortality rates. Instead,
by making the assumption that the age relationship of mortality is a scaled-up or scaled-down version of that of a standard population, it is possible to calculate an indirectly
standardised mortality ratio expressing the country's mortality relative to that of the standard population. Panels (b), (c) and (d) calculate the indirectly standardised mortality
ratio for the same country data as the corresponding panels in Figure 1, but with the age breakdown of deaths concealed.
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Table 1
Global burden of IHD deaths (thousands).
Data from the World Health Organisation 2008. Ranked by country burden.
High income countries East Asia and Paciﬁc Europe and Central Asia Latin American and the Caribbean Middle East and North Africa South Asia Sub-Saharan Africa
Rank Country Number Rank Country Number Rank Country Number Rank Country Number Rank Country Number Rank Country Number Rank Country Number
1 USA 445.8 1 China 1040.6 1 Russian
Federation
659.5 1 Brazil 133.9 1 Iran 88.0 1 India 1248.0 1 Nigeria 71.6
2 Germany 155.8 2 Indonesia 242.8 2 Ukraine 338.1 2 Mexico 77.0 2 Egypt 78.8 2 Pakistan 195.5 2 Ethiopia 43.5
3 Japan 105.5 3 Myanmar 58.2 3 Turkey 81.2 3 Argentina 36.4 3 Morocco 33.7 3 Bangladesh 163.4 3 Sudan 39.2
4 United
Kingdom
92.3 4 Philippines 57.8 4 Romania 56.7 4 Colombia 27.7 4 Iraq 26.7 4 Afghanistan 30.9 4 Dem Republic
Congo
27.0
5 Italy 87.8 5 Thailand 53.3 5 Belarus 56.1 5 Venezuela 21.2 5 Yemen 17.7 5 Nepal 21.1 5 South Africa 20.5
6 Poland 79.0 6 Malaysia 22.7 6 Uzbekistan 51.7 6 Cuba 18.2 6 Algeria 14.7 6 Sri Lanka 15.9 6 Tanzania 19.1
7 Spain 43.5 7 Cambodia 9.1 7 Kazakhstan 48.3 7 Chile 9.8 7 Syrian Arab
Republic
14.3 7 Bhutan 0.9 7 Côte d'lvoire 14.9
8 France 42.6 8 Lao People's
Republic
5.7 8 Bulgaria 23.1 8 Dominican
Republic
9.7 8 Tunisia 10.1 8 Maldives 0.1 8 Uganda 13.5
9 Canada 42.0 9 Papua New
Guinea
4.5 9 Georgia 20.0 9 Peru 9.2 9 Libyan Arab
Jamahiriya
6.7 9 Kenya 13.5
10 Hungary 33.6 10 Mongolia 1.1 10 Serbia 17.5 10 Honduras 6.2 10 Lebanon 5.9 10 Ghana 13.1
11 Czech
Republic
28.5 11 Fiji 0.8 11 Azerbaijan 16.3 11 El Salvador 4.9 11 Jordan 4.7 11 Mozambique 12.9
12 Australia 24.9 12 Timor-Leste 0.5 12 Republic of
Moldova
16.2 12 Ecuador 4.4 12 Djibouti 0.8 12 Cameroon 11.3
13 Saudi Arabia 20.9 13 Solomon
Islands
0.2 13 Lithuania 14.9 13 Guatemala 4.4 13 Malawi 9.4
14 Republic of
Korea
20.5 14 Samoa 0.1 14 Kyrgyzstan 12.9 14 Uruguay 4.0 14 Angola 7.6
15 Slovakia 18.4 15 Vanuatu 0.1 15 Turkmenistan 11.7 15 Paraguay 3.1 15 Madagascar 7.4
16 Sweden 17.0 16 Tonga 0.1 16 Armenia 10.5 16 Jamaica 3.1 16 Somalia 7.1
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High income countries East Asia and Paciﬁc Europe and Central Asia Latin American and the Caribbean Middle East and North Africa South Asia Sub-Saharan Africa
Rank Country Number Rank Country Number Rank Country Number Rank Country Number Rank Country Number Rank Country Number Rank Country Number
17 Austria 14.6 17 Latvia 9.9 17 Nicaragua 3.1 17 Zambia 6.9
18 Belgium 13.9 18 Tajikistan 6.7 18 Haiti 2.9 18 Guinea 5.7
19 Greece 13.1 19 Bosnia and
Herzegovina
5.5 19 Costa Rica 2.8 19 Chad 5.3
20 Netherlands 12.7 20 Albania 5.4 20 Panama 1.7 20 Zimbabwe 5.2
21 Croatia 12.3 21 Montenegro 0.6 21 Guyana 0.9 21 Burkina Faso 5.1
22 Finland 11.4 22 Suriname 0.4 22 Benin 4.1
23 Portugal 10.4 23 St Vincent and
Grenades
0.1 23 Mali 4.0
24 Switzerland 9.8 24 Belize 0.1 24 Niger 3.7
25 Denmark 6.7 25 Saint Lucia 0.1 25 Burundi 3.6
26 Norway 6.0 26 Grenada 0.1 26 Senegal 3.5
27 New Zealand 5.7 27 Rwanda 3.4
28 Ireland 5.3 28 Togo 2.9
29 Estonia 4.9 29 Republic 2.8
30 Singapore 4.7 30 Congo 2.1
31 Israel 4.7 31 Sierra Leone 1.8
32 Slovenia 2.4 32 Liberia 1.6
33 Oman 2.2 33 Eritrea 1.5
34 Trinidad and
Tobago
1.7 34 Mauritius 1.4
35 Kuwait 1.2 35 Lesotho 1.4
36 United Arab
Emirates
1.2 36 Namibia 1.3
37 Cyprus 1.0 37 Mauritania 1.2
38 Malta 0.7 38 Guinea-Bissau 1.0
39 Luxemberg 0.5 39 Botswana 0.8
40 Iceland 0.4 40 Gabon 0.8
41 Equatorial
Guinea
0.4 41 Swaziland 0.7
42 Bahrain 0.2 42 Gambia 0.7
43 Qatar 0.2 43 Comoros 0.3
44 Barbados 0.2 44 Cape Verde 0.2
45 Bahamas 0.1 45 Principe 0.1
46 Brunei
Darussalam
0.1
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2.1. Data sources
IHD mortality data (ICD9 codes 410–414 and ICD10 codes I20–25) between 1995
and 2009 were extracted from the online World Health Organisation (WHO) mortality
database [13] and from WHO publications [14,15]. These data comprise all deaths reg-
istered by national civil registration systems which were submitted to WHO, with un-
derlying cause of death coded by the relevant national authority using the
International Statistical Classiﬁcation of Diseases and Related Health Problems (ICD)
9th or 10th revision [16]. In some countries data were only available for parts of this
time period: in these cases the available years are shown. Population data were from
UN population estimates also available online [17]. For comparisons by region and
country income group, we have used 2001 data from the WHO, which are the most
complete.
2.2. Statistics
.2.2.1. Age-speciﬁc and age-standardised mortality rates
Age speciﬁc mortality rates for each ﬁve year age group are presented. In addition
we present directly standardised IHD mortality rates (standardised to WHO world
standard population) [18] to allow comparison of mortality rates between countries.
We also present indirectly standardised ratios for countries where direct standardisation
is not possible, by calculating deaths expected if a country had the same age-speciﬁc death
rate as the standard population (deﬁned here as the average age-speciﬁcmortality rates in
2001 of the UK, USA, Canada, France and Germany).
The authors of this manuscript have certiﬁed that they comply with the principles
of ethical publishing in the International Journal of Cardiology.
These authors take responsibility for all aspects of the reliability and freedom from
bias of the data presented and their discussed interpretation.
3. Results
3.1. Burden of IHD worldwide in 2008
In 2008 there were 7,249,000 deaths from IHD, accounting for
12.7% of all global deaths. India and China together had over 2 million
deaths or over 30% of the world's total IHD burden (Table 1). Large
numbers of deaths were also seen in the Russian Federation (659,000)
and in USA (445,800) reﬂecting their large population sizes.
Worldwide in 2001 [15], IHD was the leading cause of death in both
low-and-middle income countries (11.8% of all deaths) and high in-
come countries (17.3% of all deaths). At that time IHD was the leading
cause of death in all but two world regions: Sub-Saharan Africa and
East Asia and the Paciﬁc. IHD was the leading cause of death in Europe
and Central Asia (29.7% of total deaths), Middle East and North Africa
(16.9% of total deaths), South Asia (13.6% of total deaths) and Latin
America (10.9% of total deaths). In contrast, in Sub-Saharan Africa IHD
was the eighth cause of death after HIV/AIDS, malaria, lower respiratory
tract infections, diarrhoeal disease, perinatal conditions, measles, cere-
brovascular disease, accounting for only 3.2% total deaths. In East Asia
and the Paciﬁc, IHD was the third leading cause of death accounting
for 8.8% of total deaths.
3.2. Impact of age on IHD mortality
Fig. 3 shows the progressive increase in IHD mortality with age in
4 selected countries: UK, USA, Japan and France. In the years illustrat-
ed, women have a lower IHD mortality rate than men. There is a pro-
gressive increase in IHD mortality with age, which ﬁts an exponential
trend. In these countries, chosen for illustration because they have
complete data, there is a 2.3 to 2.7-fold increase in IHD mortality for
every decade of life for men and a 2.9 to 3.7-fold increase for
women. Fig. 4 illustrates that the exponential rise in mortality with
age is present in all countries regardless of starting mortality level
or country income level.
3.3. Age speciﬁc mortality rates from IHD in 2001
Age speciﬁc mortality rates for IHD were higher in low-and-
middle income countries than in high income countries (Tables 2aand 2b). For older ages highest rates were seen in Europe and Central
Asia, South Asia and the Middle East and North Africa. For example,
for men in the age range 80 years and over the death rates per
100,000 population were 8598 in Europe and Central Asia, 3758 in
Middle East and North Africa and 3644 in South Asia. Meanwhile in
high income countries the rate was 2253 per 100,000 population.
The difference in mortality between regions was even more
marked for premature IHD mortality in the working-age population
(deﬁned as those aged b60 years). In men this was again highest
in Europe and Central Asia and then Middle East and North Africa
and South Asia. For example, in men in the age range 45–59 years
the death rate in Europe and Central Asia was 517 per 100,000
population, in Middle East and North Africa 304 and in South Asia
302. By contrast in high income countries, the IHD death rate in
the same age group was 91 per 100,000 population, less than
one-ﬁfth of the mortality seen in low-and-middle income Europe
and Central Asia.
3.4. Time trends in age-standardised IHD mortality rates
Time series of directly-standardised IHD mortality rates between
2000 and 2009 (standardised to the WHO world standard popula-
tion) are shown for selected countries with available data in
Table 3.
Age-standardisation is essential when comparing countries, as
shown in Fig. 5a and b which contrast the crude and age-standardised
mortality trends amongst the same set of countries. A decrease in
age-standardised mortality rates is seen in most countries in Western
Europe, but countries in Eastern Europe have aﬂat pattern (Croatia, Ser-
bia, Slovakia, Hungary and Czech Republic) and an increasing trend can
be seen in some Central Asian countries (e.g. Kyrgyzstan).
In the majority of countries for which age-speciﬁc data are avail-
able, there has been a steady decline in IHD death rates between
2000 and 2009. These data tend to be for high income countries.
Reporting of time trends in IHD mortality is limited for most
low-and-middle income countries.
3.5. Extended analysis across 177 countries: standardised mortality
ratios
In order to compare a more comprehensive set of low, middle and
high income countries that do not have complete age-speciﬁc IHD
death data, we use indirectly standardised IHD mortality ratios
presented in Table 4. Countries are ranked by their 2008 IHD mortal-
ity ratio. The spectrum is wide, with some countries such as Turk-
menistan, Afghanistan and Ukraine having a mortality ratio that is
approximately 20-fold that of other countries such as Japan.
4. Discussion
IHD has been, and continues to be, the single largest cause of
death in the world. This is because the majority of the world's pop-
ulation lives in low-and-middle income countries, where IHD
mortality rates are often ﬂat or increasing, and total populations
are growing.
Overall, age-standardised mortality has fallen signiﬁcantly in
many high income countries since the early 1980s [19]. However,
the age effect on IHD mortality is so strong that high income coun-
tries, which have older and ageing populations, have a total mortality
burden which remains high and is falling only slowly over time.
The larger populations and higher age-speciﬁc death rates for IHD
in low-and-middle income countries mean that they already account
for the majority of global IHD deaths and will bear the brunt of the
IHD epidemic in the years to come. Moreover the combined effect of
population growth and ageing is so strong that despite all current ef-
forts, total numbers of IHD deaths worldwide are increasing.
Fig. 3. Change in mortality with age in UK, USA, Japan and France.
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mortality in high income countries, three may be particularly impor-
tant [20]. Firstly, policy changes may favour risk factor modiﬁcation,Fig. 4. IHD mortality by population age group for selected countries. Age-speciﬁc mor-
tality rate for selected countries. The most recent year of available data between 2005
and 2009 is displayed.such as decreased exposure to tobacco smoke [21] and improvement
in primary prevention strategies [22,23] (e.g. hypertension control
[24–26]). Second, rapid response times and improved treatments
(such as thrombolysis and primary angioplasty) for acute IHD events
may lead to reduced IHD case-fatality [27]. Third, secondary prevention,
whichmay further reducemortality, ismakingmore headway in imple-
mentation in wealthier countries [28].
The contribution of these factors to the decreasing mortality rates
from IHD is complex. The WHO MONICA (MONitoring trends and de-
terminants In CArdiovascular disease) study [29,30] reported that be-
tween the mid-1980s and 1990s, on average two thirds of the decline
in mortality from IHD could be attributed to a decline in coronary
event rates and one third to decreasing case-fatality. A more recent
study by Smolina et al. [31] during the 2000s in England reported
just over half of the decline in IHD mortality could be attributed to a
decline in event rates and just less than half to improved survival at
thirty days.
The increasing mortality in some countries in Eastern Europe is
likely to reﬂect a combination of continued high exposure to cardio-
vascular risk factors (including tobacco smoke [32]) and inadequate
prevention strategies e.g. poor control of hypertension [33,34]. In ad-
dition, evidence suggests a positive association between excess alco-
hol consumption in Eastern European countries and increased
mortality from cardiovascular disease [35]. Unfortunately, data are
sparse for many areas of the world e.g. Latin America, Africa that are
likely to be incurring continued unfavourable trends in IHD mortality
due to rapid urbanisation and the shifting focus of tobacco companies
and processed food and drinks manufacturers to low-and-middle
Table 3
Age-standardised IHD mortality for selected countries between 2000 and 2009. Data directly standardised to WHO world standard population.
Standardised mortality rates from ischaemic heart disease (per 100,000 population)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Australia 21.7 20.4 18.9 17.7 16.6 13.5
Austria 23.7 21.8 19.9 19.4 18.8 18.5 17.1 17.3
Bulgaria 34.3 31.8 29.1 27.0
Canada 22.9 21.3 20.0 19.5 18.1
Croatia 39.1 33.4 31.8 36.1 31.5 32.8 31.3 29.5 29.8 30.4
Cyprus 16.7 17.6 15.9 18.5 15.7
Czech Republic 39.7 38.0 36.4 35.1 32.7 33.9 31.9 34.7 32.5 31.4
Denmark 21.8 21.7 18.8 17.5 16.2 14.7 13.5
Egypt 14.9 17.3 22.6 23.4 20.1
Estonia 67.8 66.3 63.1 59.9 55.1 50.4 48.8 46.1 42.0
Finland 35.1 32.3 31.4 29.8 27.8 26.2 25.5 24.6 23.3 22.4
France 9.9 9.4 8.9 8.6 8.0 7.7 7.1 6.8
Germany 25.0 23.7 22.9 22.3 20.7 19.4 18.4
Hong Kong 9.6 9.7 10.3 10.4 10.0 9.2 10.1 9.8 9.3
Hungary 49.1 46.1 45.0 46.8 46.9 52.4 48.7 46.0 43.8 43.6
Iceland 23.1 21.2 22.3 19.3 21.6 17.5 16.2 16.8 16.4
Israel 18.8 16.8 15.3 15.0 12.9 12.4 12.2 12.5
Japan 7.1 7.0 6.8 6.7 6.3 6.5 6.2 6.0 5.9 5.7
Kuwait 26.4 27.9 27.0 25.3 25.2 30.2
Kyrgyzstan 71.8 69.4 78.6 81.8 77.5 84.1 90.2 88.4 90.0 91.5
Latvia 65.6 64.9 62.3 60.7 61.0 61.3 60.4 62.3 56.1 54.5
Lithuania 57.4 62.8 62.3 62.6 61.7 64.9 64.0 62.5 58.9 56.1
Luxembourg 18.3 16.4 15.9 18.7 16.1 13.3 15.4 13.1 12.1
Malta 35.4 33.9 30.8 30.9 26.5 30.2 27.9 24.0 24.7
Netherlands 18.9 17.2 16.2 15.4 13.5 12.6 11.3 10.3 9.6 8.9
New Zealand 27.5 27.7 26.1 24.2 23.8 20.8 20.1 19.1
Norway 23.4 22.1 20.9 18.7 17.0 15.0 14.1 13.6 12.9 12.2
Poland 31.3 29.4 27.2 26.6 25.2 24.1 23.5 22.4 21.5
Romania 47.8 47.3 48.3 46.6 44.5 44.0 42.8 40.6 39.3 37.9
Serbia 28.7 28.0 28.7 28.7 28.1 31.4 30.4 27.9 27.3 26.5
Slovakia 59.0 53.9 52.4 53.2 52.5 50.8
Slovenia 20.8 20.0 17.6 18.3 16.5 16.0 14.0 13.9 14.4 13.3
Spain 13.7 13.1 12.7 12.5 11.7 11.5 10.6 10.1 9.5
Sweden 24.5 23.5 22.7 21.7 19.9 18.9 18.2 17.2 16.5
United Kingdom 29.3 27.7 26.2 24.0 22.4 20.6 19.4 18.2 16.7
USA 29.7 28.2 27.2 25.9 24.0 23.1
Table 2a
Age speciﬁc death rates from IHD in 2001 (Male).
Data from the World Health Organisation.
Regions Age speciﬁc death rates from IHD (per 100,000 population)
0–4 5–14 15–29 30–44 45–59 60–69 70–79 80+
Low income countries
East Asia and Paciﬁc 1 1 3 15 79 304 779 1606
Europe and Central Asia 0 0 6 89 517 1591 3571 8598
Latin America and Caribbean 0 0 3 17 126 414 939 1956
Middle East and North Africa 0 0 5 45 304 956 2156 3758
South Asia 2 2 5 35 302 1005 2207 3644
Sub-Saharan Africa 0 0 1 14 139 526 1345 2291
High income countries
High income countries 0 0 1 13 91 298 805 2253
Table 2b
Age speciﬁc death rates from IHD in 2001 (Female).
Data from the World Health Organisation.
Age Speciﬁc Death Rates from IHD (per 100,000 population)
Regions 0–4 5–14 15–29 30–44 45–59 60–69 70–79 80+
Low income countries
East Asia and Paciﬁc 0 0 3 8 47 227 647 1776
Europe and Central Asia 0 0 2 16 132 666 2261 7911
Latin America and Caribbean 0 0 1 7 55 223 567 1758
Middle East and North Africa 0 0 2 16 137 587 1565 3618
South Asia 2 1 9 25 163 790 1945 3217
Sub-Saharan Africa 0 0 1 6 86 410 1041 2212
High income countries
High income countries 0 0 0 3 23 107 401 1789
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Fig. 5. (a). Changes in crude annual mortality rates from ischaemic heart disease for selected Countries between 2000 and 2009. (b). Changes in directly standardised annual mor-
tality rates from ischaemic heart disease for selected Countries between 2000 and 2009.
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ed with risk factors related to IHD [37] e.g. smoking, high BMI, poor
blood pressure control and lower physical activity. Without accurate
baseline mortality data it will be difﬁcult to target prevention strate-
gies for the future.5. Limitations
A major limitation to our analysis of world-wide IHD trends is the
paucity of data from certain geographical areas such as Latin America
and Africa. The majority of data currently reported to the WHO is
from high income countries with poor representation from low-
and-middle income countries.
Despite the existence of the WHO ICD coding system which tries to
standardise cause of death coding, there may still be differences in
reporting patterns between countries, for example in the handling of
deaths where multiple causes may have contributed, or where back-
ground medical information is scarce. In addition the validity of the
ICD code assignedmay vary from place to place. This may lead to either
over or under-reporting of death due to ischaemic heart disease. In ad-
dition, the uncertainty around cause of death codingmay be exaggerat-
ed in low-and-middle income countries, as some large countries such as
India and China have not implemented fully comprehensive death reg-
istration systems but rely on sample surveillance for vital statistics
[38,39].
Although low-and-middle income countries will struggle more
than high income countries to ﬁnd resources to target IHD preven-
tion, it is in these countries that the impact could be greatest as
they have the highest age-speciﬁc death rates in younger people.
IHD contributes substantially to premature mortality in these
populations, and reducing IHD mortality will increase the lifespan of
working-age populations, andmay therefore have an important effect
on economic growth [40]. Not all preventative strategies will be pro-
hibitively expensive. For example generic aspirin and statins areavailable cheaply, and government initiatives to reduce smoking
need not be ﬁnancially demanding [41]. While we acknowledge that
many low-and-middle income countries may have competing
healthcare priorities, this paper highlights the burden of IHD, and
the critical need to target preventative and treatment interventions
for IHD in these areas. It is particularly important that we do not hast-
ily assume intervention in these countries would be futile, since they
now bear the majority of the global burden of IHD deaths [42,43]. The
impact of prevention and treatment strategies has been projected for
non-communicable diseases in low-and-middle income countries
and can potentially reduce age standardised death rates by 2% per
year [44].6. Conclusion
This paper illustrates mortality trends from IHD between 1995
and 2009 derived from WHO international data. IHD mortality rises
sharply with age and IHD thus remains the leading cause of
death even in high income countries where age-standardised death
rates have fallen by as much as 50% in the last 25 years, as their
populations age. In addition, premature mortality (at age
b60 years) from IHD is far from trivial, and age-speciﬁc death rates
in the working age population are much higher in low-and-middle
income countries than high income countries. This, combined
with the large number of persons at risk in this age group in
low-and-middle income countries, makes IHD a particular challenge
for these countries.
Rising trends in IHD mortality are not inevitable as the declining
age-standardised mortality rates in many high income countries
demonstrate. Reliable information is the ﬁrst step to successful initia-
tives to tackle this potentially tractable but currently uncontrolled ep-
idemic. The opportunities are great because — unlike many other
causes of death — the susceptibility of IHD to prevention and treat-
ment is exquisite.
Table 4
Indirectly standardised mortality ratios (SMR)a for IHD for all WHO member states ranked by country SMR in 2008.
Year '95 '96 '97 '98 '99 '00 '01 '02 '03 '04 '05 '06 '07 '08 '09
Turkmenistan 536
Afghanistan 489
Ukraine 482
Kazakhstan 437
Belarus 414
Kyrgyzstan 288 288 327 339 320 357 386 387 401 397
Uzbekistan 288 306 400
Moldova 409 351 341 382 384 372 398 410 390 416 394 389 377 388
Russian Federation 349
Georgia 249 246 267 258 329
Yemen 318
Armenia 302
Somalia 300
Sudan 296
Bhutan 291
Azerbaijan 291
Pakistan 290
Oman 282
Guyana 139 136 178 192 195 186 281
Lithuania 264 251 237 262 263 265 265 283 283 282 275 271
Iraq 275
Tajikistan 273
Libya 270
Bangladesh 261
Laos 257
Slovakia 211 206 208 209 213 229 222 217 224 222 223 251 248
Myanmar 243
Malawi 240
Côte d'Ivoire 237
Saudi Arabia 236
Iran 232
Jordan 227
India 226
Latvia 252 250 267 246 242 232 223 223 227 225 220 240 216 215
Egypt 216
Morocco 214
Guinea-Bissau 212
Turkey 211
Lebanon 207
Indonesia 207
Gambia 206
Nepal 201
Zambia 200
Swaziland 197
Timor-Leste 195
Estonia 253 273 256 252 249 245 239 219 208 206 198 194 184
Albania 193
Guinea 192
Mozambique 191
Cambodia 190
Hungary 181 179 182 182 172 173 172 182 185 213 202 194 190 192
Honduras 189
Malaysia 188
Syria 188
Philippines 103 110 114 129 129 184
Ethiopia 182
Cameroon 182
Angola 181
91 94 103 79 98 115 134 140 181
Uganda 180
Liberia 178
Trinidad and Tobago 206 172 172 179 172 166 166 177
Congo 174
Benin 173
Namibia 173
Sierra Leone 170
Equatorial Guinea 170
Romania 186 176 177 182 178 174 176 176 171 169 169
Burkina Faso 163
Comoros 162
Togo 161
Burundi 160
Ghana 160
Congo 160
Czech Republic 188 172 161 148 151 144 142 139 137 130 144 142 162 159 159
St Vincent and Grenadines
Indirectly standardised mortality ratios for ischaemic heart disease 
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Lesotho 158
Tanzania 156
Nigeria 154
Mauritania 153
Tunisia 151
Viet Nam 143
United Arab Emirates 143
Kuwait 97 87 100 102 101 87 94 94 95 104 115 121 115 142 162
Senegal 142
Mali 138
Year '95 '96 '97 '98 '99 '00 '01 '02 '03 '04 '05 '06 '07 '08 '09
Venezuela 94 92 97 98 101 106 105 113 113 115 119 125 136
Croatia 128 123 128 128 121 126 120 119 141 124 134 132 131 136 142
Rwanda 134
Eritrea 132
Jamaica 129
Kenya 129
Madagascar 125
Niger 124
Bolivia 124
Botswana 121
Macedonia 120
Finland 130 127 129 130 130 125 128 124 117 118 118 119 118 116
Mauritius 132 134 127 118 117
Nicaragua 118
Bosnia and Herzegovina 115
Malta 107 113 123 114 128 122 120 115 119 108 128 125 109 113
Suriname 39 38 47 49 62 60 67 76 113
Republic of Korea 112
Cuba 105 99 104 106 113 106 107 111
Bulgaria 136 126 117 110
Zimbabwe 110
El Salvador 108
Singapore 106
Colombia 76 77 83 85 87 87 94 100 101 102 105
Mongolia 100
China 99
Paraguay 48 30 41 38 35 38 38 37 48 48 57 98
Sri Lanka 97
South Africa 58 46 51 54 55 56 58 63 60 61 62 59 97
Algeria 96
USA 113 109 107 105 102 96 95 95
Grenada 43 54 52 74 72 75 58 94
Sao Tome and Principe 93
New Zealand 97 103 102 101 102 94 96 91 92
Serbia 77 79 83 83 87 88 88 101 99 92 92 92
Ireland 98 91 94
Germany 103 101 97 96 95 95 88 86 83 90
Austria 102 98 93 93 93 94 90 93
Thailand 89
Poland 103 100 97 93 93 90 90 90 87 88
Iceland 101 96 90 102 89 82 92 89 91 78 84 80 87 81
Sweden 112 111 108 103 101 101 98 92 90 90 86 84
Argentina 82
Montenegro 81
Mexico 59 61 61 63 67 70 70 73 74 75 80
Uruguay 62 65 66 59 59 55 79
Canada 79 77 76 76 73 78
Haiti 77
United Kingdom 104 101 98 91 87 81 79 76 71
Australia 85 83 80 79 78 76 74 66 75
Brazil 106 106 109 110 113 114 117 60 63 61 65 67 69
Panama 52 49 52 54 55 59 61 65 73 68
Costa Rica 61 62 68 72 72 71 70 72 68 71 68 68 68
Denmark 128 111 109 101 100 92 94 83 79 72 68 63 67
Belize 73 60 41 84 53 60 57 41 65 51 61 67
Belgium 63 59 57 55 67
Cape Verde 66
Switzerland 66
Norway 103 104 101 100 94 91 90 84 78 70 67 67 65 62
Italy 60 54 55 64
Table 4 (continued)
(continued on next page)
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Brunei Darussalam 62
Chile 48 49 49 47 48 48 50 49 49 49 50 61
Bahamas 75 82 79 51 42 51 57 60
Greece 60
Slovenia 80 82 77 73 71 65 69 62 63 55 57 59 58
Saint Lucia 26 33 34 34 25 30 32 27 32 54 56
Israel 81 69 69 65 62 64 57 58 58 63 56
Qatar 67 44 61 64 56 55 54
Maldives 55
Peru 11 21 28 54
Barbados 51 36 40 52 34 48 54
Cyprus 51 56 55 62 54
Luxembourg 65 58 62 58 57 69 59 53 62 54 52
Guatemala 39 44 47 48
Hong Kong 32 33 37 40 40 37 44 46 43
Bahrain 118 74 77 66 58 64 64 46 38 34 41 42 38
Netherlands 75 71 70 67 64 61 58 57 52 49 46 43 42 39
Spain 47 45 45 45 46 45 45 43 43 41
Argentina 47 50 52 48 47 45 45 42 44 43 44 41
Portugal 48 48 41 39 38
Ecuador 22 25 27 26 26 29 26 26 28 29 31 31 25
France 36 35 34 34 32 32 31 30 30
French Guiana 20 23 24 21 20 16 27
Japan 25 23 23 23 24 23 23 23 24 23 25 25 24 25 25
Martinique 16 14 12 16 13 14 15 16
Guadeloupe 15 12 17 17 18 16 16 15
Year '95 '96 '97 '98 '99 '00 '01 '02 '03 '04 '05 '06 '07 '08 '09
a Standard population is deﬁned as the average age-speciﬁc mortality rates of the UK, USA, Canada, France and Germany in 2001.
Table 4 (continued)
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